Exposure to children as a risk factor for bacteremic pneumococcal disease: changes in the post-conjugate vaccine era

Joshua P Metlay1, Ebbing Lautenbach, Yimei Li

  • 1Department of Medicine, University of Pennsylvania School of Medicine, 712 Blockley Hall, 423 Guardian Dr, Philadelphia, PA 19104, USA. jmetlay@mail.med.upenn.edu

Insights

Pneumococcal conjugate vaccine introduction shifted disease serotypes. Non-vaccine serotypes increased, while vaccine types declined, leading to an overall rise in adult bacteremic pneumococcal disease.

Area of Science:

  • Epidemiology
  • Infectious Diseases
  • Vaccinology

Background:

  • Pneumococcal conjugate vaccines (PCVs) have altered the landscape of bacteremic pneumococcal disease (BPD).
  • Shifts in circulating serotypes causing BPD necessitate ongoing surveillance.
  • Understanding evolving risk factors is crucial for public health strategies.

Purpose of the Study:

  • To analyze recent trends in pneumococcal serotypes causing BPD in adults.
  • To identify current risk factors associated with BPD in the post-PCV era.

Main Methods:

  • Retrospective analysis of hospitalized adult patients with community-acquired BPD.
  • Data collected from 48 acute care hospitals in the Philadelphia region (2002-2008).
  • Serotyping of isolates and comparison of patient characteristics with regional population data.

Main Results:

  • Annual BPD rates due to vaccine serotypes decreased by 29%, while non-vaccine serotypes increased by 13%.
  • Overall adult BPD rates increased by 7% annually.
  • Advanced age, African American ethnicity, smoking, and diabetes were significant risk factors.
  • Increased number of children in the household was associated with decreased risk.

Conclusions:

  • Emerging non-vaccine serotypes are replacing those targeted by current PCVs.
  • Established risk factors like age and comorbidities persist.
  • Household transmission dynamics may be shifting, potentially influenced by PCV introduction.
Abstract

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Vaccinations01:51

Vaccinations

Overview
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...